Charles River Laboratories International (CRL) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Charles River Laboratories International (NYSE: CRL):

• 8/17/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 8/9/2025 – Charles River Laboratories International was upgraded by analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating.
• 8/8/2025 – Charles River Laboratories International had its price target raised by analysts at Evercore ISI from $180.00 to $190.00. They now have an “outperform” rating on the stock.
• 8/7/2025 – Charles River Laboratories International had its price target raised by analysts at JPMorgan Chase & Co. from $145.00 to $160.00. They now have a “neutral” rating on the stock.
• 8/7/2025 – Charles River Laboratories International had its price target raised by analysts at Barclays PLC from $155.00 to $165.00. They now have an “equal weight” rating on the stock.
• 7/9/2025 – Charles River Laboratories International had its price target raised by analysts at Evercore ISI from $170.00 to $180.00. They now have an “outperform” rating on the stock.
• 7/9/2025 – Charles River Laboratories International was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $200.00 price target on the stock, up previously from $150.00.
• 7/5/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 6/27/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the transaction, the executive vice president owned 24,116 shares in the company, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).